Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPG 10101 combination therapy for the treatment of hepatitis C: a phase II randomized, open label, multi-center, parallel arm, controlled trial of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) or PEG-IFN plus RVN without CPG 10101 in the treatment of non-responder (null and partial responder) HCV [hepatitis C virus] genotype 1 infected subjects.

Next Previous
X
Search
Trial Profile

CPG 10101 combination therapy for the treatment of hepatitis C: a phase II randomized, open label, multi-center, parallel arm, controlled trial of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) or PEG-IFN plus RVN without CPG 10101 in the treatment of non-responder (null and partial responder) HCV [hepatitis C virus] genotype 1 infected subjects.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPG 10101 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 07 Jun 2007 The expected completion date for this trial is now 1 Jul 2008.
    • 13 Mar 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top